Spots Global Cancer Trial Database for tki 258
Every month we try and update this database with for tki 258 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | NCT01379534 | Solid Tumors an... Endometrial Can... Second-line Tre... VEGF | TKI258 | 18 Years - | Novartis | |
A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients | NCT01576380 | Adenocarcinoma,... Linitis Plastic... Stomach Neoplas... Stomach Disease... Neoplasms by Si... Neoplasms | TKI258 | 20 Years - | Novartis | |
Safety of CHIR-258 (TKI258) in Advanced Solid Tumors | NCT01270906 | Neoplasms Cancer Tumors | CHIR-258 (TKI25... | 18 Years - | Novartis | |
A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients | NCT01576380 | Adenocarcinoma,... Linitis Plastic... Stomach Neoplas... Stomach Disease... Neoplasms by Si... Neoplasms | TKI258 | 20 Years - | Novartis | |
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | NCT01379534 | Solid Tumors an... Endometrial Can... Second-line Tre... VEGF | TKI258 | 18 Years - | Novartis |